Profile data is unavailable for this security.
About the company
Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
- Revenue in SEK (TTM)35.75m
- Net income in SEK-134.15m
- Incorporated1999
- Employees52.00
- LocationSenzime AB (publ)Ulls Vag 41UPPSALA 756 51SwedenSWE
- Phone+46 18515640
- Fax+46 18515630
- Websitehttps://senzime.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boule Diagnostics AB | 571.33m | 25.08m | 387.55m | 228.00 | 15.67 | 0.8157 | 7.40 | 0.6783 | 0.6368 | 0.6368 | 14.64 | 12.23 | 0.7542 | 4.67 | 3.84 | 2,505,829.00 | 3.28 | 1.67 | 4.48 | 2.40 | 43.69 | 43.50 | 4.35 | 2.04 | 1.07 | 4.27 | 0.2591 | 42.24 | 4.24 | 6.13 | 96.24 | -9.45 | -9.74 | -- |
| Karolinska Development AB | 1.94m | 33.61m | 416.80m | 8.00 | 12.51 | 0.3371 | 12.09 | 215.18 | 0.1245 | 0.1245 | 0.0072 | 4.62 | 0.0016 | -- | 1.66 | 242,125.00 | 2.71 | 3.37 | 2.73 | 3.83 | -- | -- | 1,734.95 | 1,466.36 | -- | -- | 0.0023 | 0.00 | -12.43 | -8.10 | 106.11 | -29.31 | -- | -- |
| BrainCool AB (publ) | 29.15m | -57.05m | 440.90m | 22.00 | -- | 3.63 | -- | 15.13 | -0.2848 | -0.2848 | 0.1465 | 0.4792 | 0.2418 | 2.09 | 3.32 | 1,214,417.00 | -47.34 | -47.14 | -56.18 | -70.16 | -50.61 | -149.77 | -195.75 | -391.45 | 0.7253 | -7.34 | 0.00 | -- | 32.06 | 78.35 | -34.34 | -- | -11.63 | -- |
| Modulight Oyj | -1.17tn | -1.17tn | 462.26m | 70.00 | -- | 0.736 | -- | -- | -- | -- | -- | 1.26 | -- | -- | -- | -- | -- | -8.39 | -- | -9.10 | -- | 114.69 | -- | -56.81 | 6.11 | -- | 0.1004 | -- | -12.48 | -8.20 | -38.69 | -- | 63.60 | -- |
| Bioretec Oy | 45.57m | -44.19m | 642.80m | 37.00 | -- | 6.43 | -- | 14.11 | -0.1984 | -0.1984 | 0.2047 | 0.4213 | 0.5524 | 1.46 | 3.68 | 105,594.60 | -53.58 | -67.11 | -65.75 | -97.60 | 69.85 | 70.97 | -96.98 | -134.05 | 4.86 | -4.02 | 0.0754 | -- | 32.77 | 19.77 | -56.82 | -- | -- | -- |
| Paxman AB (publ) | 210.12m | 8.33m | 714.87m | 91.00 | 86.28 | 5.83 | 26.53 | 3.40 | 0.4358 | 0.4358 | 11.03 | 6.45 | 1.23 | 2.70 | 7.67 | 2,308,978.00 | 4.89 | -5.08 | 6.65 | -7.76 | 69.68 | 69.38 | 3.96 | -5.07 | 1.67 | 2.71 | 0.1251 | -- | 43.99 | 29.35 | 180.69 | -- | 6.26 | -- |
| Senzime AB (publ) | 35.75m | -134.15m | 724.08m | 52.00 | -- | 2.30 | -- | 20.25 | -1.49 | -1.49 | 0.3875 | 3.14 | 0.0946 | 1.31 | 5.60 | 687,576.90 | -35.48 | -35.68 | -37.78 | -38.00 | 23.32 | -20.59 | -375.20 | -558.68 | 6.97 | -- | 0.0296 | -- | 154.77 | 61.90 | -1.09 | -- | -3.69 | -- |
| Mentice AB | 273.61m | -2.82m | 772.18m | 122.00 | -- | 4.86 | 30.91 | 2.82 | -0.1098 | -0.1098 | 10.90 | 6.22 | 0.8348 | 2.40 | 3.20 | 2,242,705.00 | -0.8595 | -7.69 | -1.69 | -13.07 | 86.39 | 83.67 | -1.03 | -10.00 | 1.01 | -- | 0.0567 | -- | 25.54 | 11.74 | 90.81 | -- | -10.83 | -- |
| Integrum AB | 96.19m | 8.26m | 911.12m | 34.00 | 114.54 | 6.41 | 87.88 | 9.47 | 0.447 | 0.447 | 5.19 | 7.99 | 0.5918 | 0.5859 | 3.83 | -- | 5.08 | -6.65 | 5.65 | -7.95 | 86.80 | 81.52 | 8.58 | -11.19 | 3.04 | -4.28 | 0.0462 | -- | 33.29 | 37.39 | -117.50 | -- | 86.42 | -- |
| OssDsign AB | 112.16m | -130.49m | 1.01bn | -- | -- | 4.30 | -- | 9.00 | -1.74 | -1.74 | 1.52 | 2.41 | 0.3408 | 6.54 | 6.19 | -- | -39.65 | -38.80 | -44.90 | -44.72 | 74.58 | 72.29 | -116.35 | -203.05 | 4.15 | -30.39 | 0.0132 | -- | 96.82 | 53.26 | -31.30 | -- | -60.35 | -- |
| Optomed Oyj | 176.12m | -51.79m | 1.06bn | 114.00 | -- | 4.39 | -- | 6.04 | -0.2695 | -0.2695 | 0.9211 | 1.15 | 0.5002 | 1.67 | 4.92 | 132,456.10 | -14.70 | -12.95 | -17.72 | -15.90 | 67.83 | 65.69 | -29.40 | -27.84 | 2.04 | -7.29 | 0.1926 | -- | 3.00 | 3.47 | 18.84 | -- | 7.26 | -- |
Data as of May 08 2024. Currency figures normalised to Senzime AB (publ)'s reporting currency: Swedish Krona SEK
30.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Mar 2024 | 8.24m | 8.19% |
| Fj�rde AP-fondenas of 14 Dec 2023 | 7.57m | 7.53% |
| Teknik Innovation Norden Fonder ABas of 14 Dec 2023 | 4.86m | 4.84% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 4.35m | 4.32% |
| Carnegie Fonder ABas of 28 Mar 2024 | 3.91m | 3.88% |
| FCG Fonder ABas of 30 Jun 2022 | 1.83m | 1.82% |
| SEB Investment Management ABas of 28 Mar 2024 | 191.36k | 0.19% |
| Alfa Kraft Fonder ABas of 31 Dec 2022 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
